Wockhardt has received tentative approval from the United States Food & Drug Administration (USFDA) for marketing the Fexofenadine HCI 60 mg plus Pseudoephedrine HCL 120 mg extended release tablets, which is used for treatment of seasonal allergic rhinitis without causing drowsiness.
Fexofenadine plus Pseudoephedrine is the generic name for the brand Allegra-D 12 hour, marketed in the United States by Sanofi Aventis. The patent covering this product is under litigation in the US courts. Wockhardt will launch the product after resolution of the same, the firm said in a statement to the stock exchanges today.